{"id":781079,"date":"2023-08-30T13:16:44","date_gmt":"2023-08-30T17:16:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/"},"modified":"2023-08-30T13:16:44","modified_gmt":"2023-08-30T17:16:44","slug":"shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/","title":{"rendered":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Apellis Pharmaceuticals, Inc..<\/strong><\/p>\n<p>Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u79tt03PG5SE7sg9x4aBAGCKTJl6sVEcZ9hxpZIvR5y_D27zebnC16-Aud-98ZfViU9FOWc-MABOGN_CUq20lsLN7hSZf0X-FC_maHw6llVrXHM_4n9aU2bs6yZCOZx7hiLoGxIhsN0eP-rVCRKFHNdKpiqjTqAb2PemTcAWuKxwRVHEx-x7TWrQRlvFzRP_9ZVTVKchk_RwlfLI9VSAiXwKtNAr_tHTwXA7HKWbP0G3GU-ToD5AbX_q4rMndBBxrnlPHa4Sna-QgkCPC7iD1Q==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/apellis-loss-submission-form\/?id=45316&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>January 28, 2021 to July 28, 2023<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants\u2019 statements about the Company\u2019s business, operations, and prospects lacked a reasonable basis.<\/p>\n<p>\n        <strong>DEADLINE: October 2, 2023<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u79tt03PG5SE7sg9x4aBAGCKTJl6sVEcZ9hxpZIvR5y_D27zebnC16-Aud-98ZfViU9FOWc-MABOGN_CUq20lsLN7hSZf0X-FC_maHw6llVrXHM_4n9aU2bs6yZCOZx7MBYmlKO2Pr_F9v9voF8eOjUnLBBFGkVWiAXsWZqgLTDBDuk1El9WL9tgY1h27vgviRN1516Zake4erL2BeRa_1zMbDSUO8u-u5jd6YErE9aj4dj5KBZjbK9mHlnMWKbvnQ04F5smCuuW_3kKkCQ5Zg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/apellis-loss-submission-form\/?id=45316&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of APLS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 2, 2023. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VsVEGLD5Vqd73T1-BPfEh32JgS0nz_4tn3-1MypHGxxbvIuWIfsReCExG7M0yTiaXvZJ_z-YNQKj0G1pYV6KJhpGyaCNKg6tYzsWRBXu4Fz7NdHGBBPTD4YG5d4xmCUd\" rel=\"nofollow noopener\" target=\"_blank\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjJkNTJlNGYtNjYzOC00ZmVlLTg3MzAtMTRjZGQ2Zjg4MmQ0LTEyNzA0Njc=\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/apellis-loss-submission-form\/?id=45316&amp;from=3 CLASS PERIOD: January 28, 2021 to July 28, 2023 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781079","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/apellis-loss-submission-form\/?id=45316&amp;from=3 CLASS PERIOD: January 28, 2021 to July 28, 2023 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was &hellip; Continue reading &quot;SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T17:16:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)\",\"datePublished\":\"2023-08-30T17:16:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/\",\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\",\"datePublished\":\"2023-08-30T17:16:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk","og_description":"NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Apellis Pharmaceuticals, Inc.. Shareholders who purchased shares of APLS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/apellis-loss-submission-form\/?id=45316&amp;from=3 CLASS PERIOD: January 28, 2021 to July 28, 2023 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the design of SYFOVRE\u2019s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was &hellip; Continue reading \"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T17:16:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)","datePublished":"2023-08-30T17:16:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/","name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=","datePublished":"2023-08-30T17:16:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzE4OCM1Nzg5MzQ2IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-apellis-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-2-2023-nasdaq-apls-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 \u2013 (NASDAQ: APLS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781079"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781079\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}